NK3 receptor antagonists: The next generation of antipsychotics?

Will Spooren*, Claus Riemer, Herbert Meltzer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

104 Scopus citations


Although current antipsychotic drugs are effective at treating the psychotic (positive) symptoms of schizophrenia, they have one or more serious side effects, including extrapyramidal symptoms, weight gain, cardiovascular liabilities and type II diabetes. However, recent data from clinical trials of selective neurokinin 3 (NK3) receptor antagonists in schizophrenia - osanetant and talnetant - have shown significant improvement in positive symptoms, with no major side-effects reported as yet. Here we discuss the preclinical and clinical evidence that indicates that NK3 receptor antagonists might represent a new approach to the treatment of schizophrenia and possibly other neuropsychiatric disorders.

Original languageEnglish (US)
Pages (from-to)967-975
Number of pages9
JournalNature Reviews Drug Discovery
Issue number12
StatePublished - Dec 1 2005

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'NK<sub>3</sub> receptor antagonists: The next generation of antipsychotics?'. Together they form a unique fingerprint.

Cite this